medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2025, Number 3

<< Back

Ginecol Obstet Mex 2025; 93 (3)

Fibroadenoma and breast cancer

Jaramillo ADS, Álvarez GJS, Cañar CAE, Zhapán SD, Quezada GAS, Quezada GIV

Language: Spanish
References: 50
Page: 103-113
PDF size: 230.28 Kb.


ABSTRACT

Background: Fibroadenomas are the most common benign breast disease. It is estimated that 10% of the female population will have a fibroadenoma at some point in their lives. Between 0.002% and 0.125% of cases will be malignant. At present, the medical approach to this problem is unclear.
Objective: To characterize fibroadenomas according to their epidemiology, etiology, diagnosis, and treatment and to describe their relationship with breast cancer.
Methodology: Narrative review of the literature on fibroadenomas and breast cancer based on the most recent and relevant information in the PubMed-Medline, Scopus, SciELO, and LILACS databases. Articles written in Spanish or English and published between 2019 and 2024 were included.
Results: Several studies associated fibroadenomas with the future development of breast cancer. The risk of breast cancer was 1.7 times higher in women with fibroadenomas than in those without.
Conclusion: Women with fibroadenomas may benefit from closer surveillance and personalized screening strategies. Further research is needed, with a focus on determining the risk of malignancy of fibroadenoma histologic subtypes and breast cancer subtypes.


REFERENCES

  1. Stachs A, Stubert J, Reimer T, Hartmann S. Benign breastdisease in women. Dtsch Ärztebl Int 2019; 116: 565-74.https://doi.org/10.3238/arztebl.2019.0565

  2. Ajmal M, Khan M, Van Fossen K. Breast fibroadenoma.In: StatPearls. Treasure Island (FL): StatPearls Publishing,2024. http://www.ncbi.nlm.nih.gov/books/NBK535345/

  3. Salati SA. Breast fibroadenomas: a review in the light ofcurrent literature. Pol J Surg 2020; 93: 40-8. https://doi.org/10.5604/01.3001.0014.5676

  4. Akin IB, Balci P. Fibroadenomas: a multidisciplinary reviewof the variants. Clin Imaging 2021; 71: 83-100. https://doi.org/10.1016/j.clinimag.2020.10.058

  5. Chen Z, Zhang Y, Li W, Gao C, et al. Single cell profiling offemale breast fibroadenoma reveals distinct epithelial cellcompositions and therapeutic targets. Nat Commun 2023;14: 3469. https://doi.org/10.1038/s41467-023-39059-3

  6. Ramala SR, Chandak S, Chandak MS, Annareddy S. A comprehensivereview of breast fibroadenoma: correlatingclinical and pathological findings. Cureus 2023; 15: e49948.https://doi.org/10.7759/cureus.49948.

  7. Tan PH. Fibroepithelial lesions revisited: implications fordiagnosis and management. Mod Pathol 2021; 34: 15-37.https://doi.org/10.1038/s41379-020-0583-3

  8. Pandit P, Murkey SP, Agarwal A, Jaiswal A, Agrawal S. Understandingfibroadenoma of the breast: a comprehensivereview of pre-operative and post-operative clinicopathologicalcorrelations. Cureus 2023; 15: e51329. https://doi.org/10.7759/cureus.51329

  9. Yu Wu, Wu YT, Wu YT, Shou Tung Chen, et al. Breast cancer arisingwithin fibroadenoma: collective analysis of case reports inthe literature and hints on treatment policy. World J Surg Oncol2014; 12: 335. https://doi.org/10.1186/1477-7819-12-335

  10. Smith GH. Two independent foci of intraduct carcinomaof the breast, one within a fibro-adenoma. J PatholBacteriol 1949; 61: 121-4. https://doi.org/10.1002/path.1700610116

  11. Krishnamurthy K, Alghamdi S, Gyapong S, Kaplan SS, et al. Aclinicopathological study of fibroadenomas with epithelialproliferation including lobular carcinoma in-situ, atypicalductal hyperplasia, DCIS and invasive carcinoma. BreastDis 2019; 38: 97-101. https://doi.org/10.3233/bd-180368

  12. Xu L, Luo S, Gao Y, Mao Q, et al. Breast carcinoma arisingin a fibroadenoma: A case series of 16 patients and reviewof the literature. Oncol Lett 2023; 27: 39. https://doi.org/10.3892/ol.2023.14172

  13. Sprague BL, Tice JA, Miglioretti DL, Li CS, et al. Breast densityand benign breast disease: risk assessment to identifywomen at high risk of breast cancer. J Clin Oncol 2015; 33:3137-43. https://doi.org/10.1200/jco.2015.60.8869

  14. Fives C, O’Neill CJ, Murphy R, Corrigan M, et al. Whenpathological and radiological correlation is achieved, excisionof fibroadenoma with lobular neoplasia on core biopsyis not warranted. The Breast 2016; 30: 125-9. https://doi.org/10.1016/j.breast.2016.09.006

  15. Saimura M, Koga K, Anan K, Mitsuyama S, et al. Diagnosis,characteristics, and treatment of breast carcinomas withinbenign fibroepithelial tumors. Breast Cancer 2018; 25: 470-8. https://doi.org/10.1007/s12282-018-0847-7

  16. Dupont William D, Page David L, Parl Fritz F, Vnencak-JonesCindy L, et al. Long-term risk of breast cancer in womenwith fibroadenoma. N Engl J Med 1994; 331: 10-5. https://doi.org/10.1056/NEJM199407073310103

  17. Guzmán M, Heron S, Martínez-Gómez E, Ramos P, et al.Fibroadenoma gigante de mama. Clínica e Investig enGinecol Obstet 2011; 38: 32-4. https://doi.org/10.1016/j.gine.2009.12.013

  18. Krings G, Bean GR, Chen YY. Fibroepithelial lesions; TheWHO spectrum. Semin Diagn Pathol 2017; 34: 438-52.https://doi.org/10.1053/j.semdp.2017.05.006

  19. Feliciano YZ, Freire R, Net J, Yepes M. Ductal and lobularcarcinoma in situ arising within an enlarging biopsyproven fibroadenoma. BMJ Case Rep CP 2021; 14: e237017.https://doi.org/10.1136/bcr-2020-237017

  20. Darooei M, Khan F, Rehan M, Zubeda S, et al. MED12somatic mutations encompassing exon 2 associated withbenign breast fibroadenomas and not breast carcinoma inIndian women. J Cell Biochem 2019; 120: 182-91. https://doi.org/10.1002/jcb.27293

  21. Johansson A, Christakou AE, Iftimi A, Eriksson M, et al.Characterization of benign breast diseases and associationwith age, hormonal factors, and family history of breastcancer among women in Sweden. JAMA Netw Open2021; 4: e2114716. https://doi.org/10.1001/jamanetworkopen.2021.14716

  22. Shaik AN, Ruterbusch JJ, Abdulfatah E, Shrestha R, et al.Breast fibroadenomas are not associated with increasedbreast cancer risk in an African American contemporarycohort of women with benign breast disease. BreastCancer Res 2018; 20: 91-91. https://doi.org/10.1186/s13058-018-1027-6

  23. Baer HJ, Schnitt SJ, Connolly JL, Byrne C, et al. Early life factorsand incidence of proliferative benign breast disease.Cancer Epidemiol Biomarkers Prev 2005; 14: 2889-97.https://doi.org/10.1158/1055-9965.EPI-05-0525

  24. Alipour S, Abedi M, Saberi A, Maleki-Hajiagha A, et al.Metformin as a new option in the medical managementof breast fibroadenoma; a randomized clinical trial. BMCEndocr Disord 2021; 21: 169. https://doi.org/10.1186/s12902-021-00824-4

  25. Zhu L, Zeng X, Jiang S, Ruan S, et al. Prevalence of breastfibroadenoma in healthy physical examination populationin Guangdong province of China: a cross-sectional study.BMJ Open 2022; 12: e057080. https://doi.org/10.1136/bmjopen-2021-057080

  26. Limaiem F, Kashyap S. Phyllodes tumor of the breast. In:Treasure Island: StatPearls Publishing, 2024. http://www.ncbi.nlm.nih.gov/books/NBK541138/

  27. Liang M, Zhang Z, Zhang C, Chen R, et al. Feasibility andefficacy of ultrasound-guided high-intensity focusedultrasound of breast fibroadenoma. Int J Hyperthermia2023; 40: 2240548. https://doi.org/10.1080/02656736.2023.2240548

  28. Wang Q, Zheng J, Ren Y, Xu H. Clinical effect of transareolarresection and minimally invasive mammotomebiopsy in the treatment of breast fibroadenoma and itsimpact on the quality of life of patients. Am J Transl Res2022; 14: 3539-46

  29. Román M, Louro J, Posso M, Vidal C, , et al. Long-term riskof breast cancer after diagnosis of benign breast disease byscreening mammography. Int J Environ Res Public Health2022; 19: 2625. https://doi.org/10.3390/ijerph19052625

  30. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancerrisk associated with benign breast disease: systematicreview and meta-analysis. Breast Cancer Res Treat 2015;149: 569-75. https://doi.org/10.1007/s10549-014-3254-6

  31. Li J, Humphreys K, Ho PJ, Eriksson M, et al. Family History,Reproductive, and lifestyle risk factors for fibroadenomaand breast cancer. JNCI Cancer Spectr 2018; 2. https://doi.org/10.1093/jncics/pky051

  32. Sneha P, Yevoor K. Study of Histopathological Changes inFibroadenoma of the Breast. Ann Pathol Lab Med 2023; 10:A13-18. https://doi.org/10.21276/apalm.3194

  33. Nutter E, Weiss JE, Marotti JD, Barth RJ, et al. Personal historyof proliferative breast disease with atypia and risk ofmultifocal breast cancer. Cancer 2018; 124: 1350-7. https://doi.org/10.1002/cncr.31202

  34. Loke BN, Nasir NDM, Thike AA, Lee JYH, et al. Genetics andgenomics of breast fibroadenomas. J Clin Pathol 2018; 71:381-7. https://doi.org/10.1136/jclinpath-2017-204838

  35. Md Nasir N, Ng C, Rajasegaran V, Wong SF, et al. Genomiccharacterisation of breast fibroepithelial lesions in aninternational cohort. J Pathol 2019; 249: 447-60. https://doi.org/10.1002/path.5333

  36. Li J, Li P, Li J, Yang H, et al. Effects of the methylationlevels for the breast cancer associated genes BCSG1 andBRCA1 on cellular proliferation and migration. Genet TestMol Biomark 2022; 26: 422-9. https://doi.org/10.1089/gtmb.2021.0304

  37. Perepechaeva M, Studenikina A, Grishanova A, GlushkovA, et al. Serum miR-181a and miR-25 in patients withmalignant and benign breast diseases. Biomed Khim 2023;69: 307-14. https://doi.org/10.1134/s1607672923700436

  38. Kara M, Kaplan M, Bozgeyik I, Özcan Ö, Çelik Öİ, Bozgeyik E,et al. MTUS1 tumor suppressor and its miRNA regulators infibroadenoma and breast cancer. Gene 2016; 587: 173-7.https://doi.org/10.1016/j.gene.2016.05.006

  39. Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, et al.PIK3CA hotspot mutation scanning by a novel and highlysensitive high-resolution small amplicon melting analysismethod. J Mol Diagn 2010; 12: 697-704. https://doi.org/10.2353/jmoldx.2010.100008

  40. Sampaio F, Marthins L, Dourado C, Revoredo C, et al. A casecontrolstudy of metallothionein-1 expression in breastcancer and breast fibroadenoma. Sci Rep 2019; 9: 7407.https://doi.org/10.1038/s41598-019-43565-0

  41. Martins LM, Carla Solange de Melo ED, Solange de Melo ED,de Melo Escórcio Dourado CS, et al. Expression of matrixmetalloproteinase 2 and 9 in breast cancer and breast fibroadenoma:a randomized, double-blind study. Oncotarget 2019;10: 6879-84. https://doi.org/10.18632/oncotarget.27347

  42. Huang KT, Dobrovic A, Yan M, Karim RZ, et al. DNA methylationprofiling of phyllodes and fibroadenoma tumoursof the breast. Breast Cancer Res Treat 2010; 124: 555-65.https://doi.org/10.1007/s10549-010-0970-4

  43. Sat-Muñoz D, Martinez-Herrera B, Quiroga-Morales L,Trujillo-Hernández B, et al. Adipocytokines and InsulinResistance: Their role as benign breast disease and breastcancer risk factors in a high-prevalence overweightobesitygroup of women over 40 years old. Int J EnvironRes Public Health 2022; 19: 6093. https://doi.org/10.3390/ijerph19106093

  44. Yustisia I, Amriani R, Cangara H, Syahrijuita S, et al. Highexpression of FBP1 and LDHB in fibroadenomas and invasivebreast cancers. Breast Dis 2021; 40: 251-6. https://doi.org/10.3233/bd-201035

  45. Elnahas W, Metwally I, Bonna K, Youssef M, AbdAllah S,Bonna M, et al. Fibroadenoma of the breast; incidenceof malignancy and indicators for surgical intervention:An analysis of 1392 patients. Breast Dis 2022; 41: 421-6.https://doi.org/10.3233/bd-210074

  46. Cheng YG, Zongqiong Sun, Zhang HX, Mao GQ. An applicationstudy of low-dose computed tomography perfusionimaging (LDCTPI) in breast cancer and breast fibroadenoma.J X-Ray Sci Technol 2018; 26: 681-90. https://doi.org/10.3233/xst-18377

  47. Du Y, Zha H ling, Wang H, Liu XS, et al. Ultrasound-basedradiomics nomogram for differentiation of triple-negativebreast cancer from fibroadenoma. Br J Radiol 2022; 95:20210598. https://doi.org/10.1259/bjr.20210598

  48. Coskunpinar E, Tiryakioğlu D, Abaci N, Tükenmez M,Pençe S. Investigation of the miR-637 and miR-523-5p as candidate biomarkers in breast cancer. BratislLek Listy 2023; 124: 814-20. https://doi.org/10.4149/bll_2023_125

  49. Saad MN, Ayeldeen G, Shaker OG. Breast cancer andfibroadenoma biomarkers detection through genetic associationstudy. Gene Rep 2020; 22: 100994. https://doi.org/10.1016/j.genrep.2020.100994

  50. Li JJX, Tse G. Core needle biopsy diagnosis of fibroepitheliallesions of the breast: a diagnostic challenge. Pathology(Phila) 2020; 52: 627-34. https://doi.org/10.1016/j.pathol.2020.06.005




2020     |     www.medigraphic.com